Aleixo André A R, Michelin Márcia A, Murta Eddie F C
Oncology Research Institute (IPON)/ Discipline of Gynecology and Obstetrics, (UFTM), Avenida Getulio Guarita, sn, Uberaba (MG), CEP 38025-440, Bairro Abadia, Brazil.
Recent Pat Endocr Metab Immune Drug Discov. 2013 Sep;7(3):226-32. doi: 10.2174/18722148113079990001.
The immune system, which is indispensible for controlling neoplasias, relies on its innate and acquired immunity components to mount an effective response against tumors. In this context, dendritic cells (DCs) are seen as the best antigen-presenting cells because of their capacity for cross-presentation, which can activate both T-helper and cytotoxic lymphocytes. Thus immunotherapy with DCs is considered promising, especially for early-stage cancers. This article provides a clarifying review of recent perspectives on the development of cancer immunotherapy, which has a wide potential for therapeutic applications, and of patents related to immunotherapy with DCs.
免疫系统对于控制肿瘤形成至关重要，它依靠其固有免疫和获得性免疫成分来对肿瘤发起有效反应。在此背景下，树突状细胞（DCs）因其具有交叉呈递能力，被视为最佳抗原呈递细胞，这种能力可激活辅助性T淋巴细胞和细胞毒性淋巴细胞。因此，DCs免疫疗法被认为具有前景，尤其是对于早期癌症。本文对癌症免疫疗法发展的近期观点以及与DCs免疫疗法相关的专利进行了清晰的综述，癌症免疫疗法具有广泛的治疗应用潜力。
